Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
Patents for C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof (30,692)
10/2001
10/30/2001US6310057 α-ketoamide multicatalytic protease inhibitors
10/30/2001US6310041 For treatment of eye disease selected from alkali-injured eye, chemically injured eye and inflammatory disease of the eye
10/28/2001CA2345569A1 Somatostatin antagonists and agonists that act at the sst subtype 2 receptor
10/25/2001WO2001079474A1 Method for modification of proteins by transglutaminase
10/25/2001WO2001079268A2 A glycopeptide and preparation thereof
10/25/2001WO2001079267A2 A glycopeptide and preparation thereof
10/25/2001WO2001079264A1 PROCESS FOR PRODUCING α-L-ASPARTYL-L-PHENYLALANINE METHYLESTER HYDROCHLORIDE
10/25/2001WO2001079263A1 Peptide derivatives and medicinal compositions
10/25/2001WO2001079262A1 Pyrazinone and pyridinone derivatives as thrombin inhibitors
10/25/2001WO2001079261A1 Tetrahydro-azepinone derivatives as thrombin inhibitors
10/25/2001WO2001079242A2 Process for preparing lipid ii and derivatives thereof
10/25/2001WO2001079195A2 Pyridine and pyrazine derivatives as thrombin inhibitors
10/25/2001WO2001079193A2 Substituted hydrazinyl heteroaromatic inhibitors of thrombin
10/25/2001WO2001079167A2 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
10/25/2001WO2001038584A3 Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
10/25/2001WO2000061541A8 Pharmaceutical compounds
10/25/2001US20010034460 Formation of ammonium salt of (alpha-aspartyl)phenylalanine by amidation of ester of (alpha-aspartyl)phenylalanine, then (alpha- aspartyl)-beta-cyclohexylalaninamide is obtained by catalytic hydrogenation
10/25/2001DE10019879A1 Production of known and new 2,5-diketopiperazine derivatives useful for the synthesis of bioactive compounds, e.g. cyclo(Lys-Lys)
10/25/2001CA2406953A1 A glycopeptide and preparation thereof
10/25/2001CA2406952A1 Process for preparing lipid ii
10/25/2001CA2406475A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
10/24/2001EP1148050A1 Retroviral protease inhibitors
10/24/2001EP1147097A1 Peptidyl heterocyclic ketones useful as tryptase inhibitors
10/24/2001EP0919567B1 Novel peptides and nootropic agent
10/24/2001EP0820433B1 O-malonyltyrosyl compounds, o-malonyltyrosyl compound-containing peptides, and uses thereof
10/24/2001CN1319008A Hydroxamate-containing cysteine and serine protease inhibitors
10/23/2001US6307101 Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
10/23/2001US6306911 Enzyme inhibitors
10/23/2001US6306892 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
10/23/2001US6306875 Growth-hormone secretagogues
10/23/2001US6306822 Phosphopeptides and methods of treating bone diseases
10/23/2001US6306663 Controlling protein levels in eucaryotic organisms
10/23/2001CA2125043C Heparin- and sulfatide-binding peptides from the type i repeats of human thrombospondin
10/18/2001WO2001077144A1 Gamma-secretase inhibitors
10/18/2001WO2001077122A1 Ternary ligand complexes useful as radiopharmaceuticals
10/18/2001WO2001077114A1 Inhibitors of prenyl-protein transferase
10/18/2001WO2001077113A2 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
10/18/2001WO2001076616A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001WO2001076393A1 Sweeteners, particularly for coffee and tea
10/18/2001WO2001025264A3 Substituted phosphinate based peptide derivatives
10/18/2001US20010031858 Coupling of 2-(2-acetylamino-3-(4-amidinophenyl) propionylamino)-2-cyclohexylacetic acid with a 3-(2-amino-2-carbamoylethyl)-1-methylpyridinium salt or a salt thereof; anticoagulants
10/18/2001US20010031732 Free radical scavenger in cosmetics, drugs
10/18/2001CA2405779A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001CA2404746A1 Sweeteners, particularly for coffee and tea
10/18/2001CA2404290A1 Ternary ligand complexes useful as radiopharmaceuticals
10/17/2001EP1146121A1 Method for modification of proteins by transglutaminase
10/17/2001EP1144436A1 METHOD FOR PREPARING BICYCLIC COMPOUNDS AND USE OF SAID METHOD FOR PREPARING AN INTERLEUKIN-1$g(B) CONVERSION ENZYME (ICE) INHIBITOR
10/17/2001EP1144435A2 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001EP1144434A2 Combinatorial process for preparing polyamines
10/17/2001EP1144365A2 Inhibitors of alpha-4 beta-1 mediated cell adhesion
10/17/2001EP1144011A2 Prodrug compounds and process for preparation thereof
10/17/2001EP1143992A2 Therapeutic compositions containing glutathione analogs
10/17/2001EP0808103A4 Protein hydroxylation inhibitors for fibroproliferative disorders
10/17/2001CN1318069A Factor VIIa inhibitors
10/16/2001US6303578 For providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence
10/16/2001US6303319 Cell based assay for identifying sh2-domain-specific signal transducer antagonist
10/11/2001WO2001074844A2 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity
10/11/2001WO2001074784A1 CYCLIC LACTAMS AS INHIBITORS OF A-β PROTEIN PRODUCTION
10/11/2001WO2001074783A1 Cyclic lactams as inhibitors of a βετα protein production
10/11/2001WO2001074768A2 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
10/11/2001US20010029259 Therapy for obesity, diabetes, sexual disorders
10/11/2001CA2405043A1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
10/11/2001CA2404023A1 Cyclic lactams as inhibitors of a.beta. protein production
10/11/2001CA2403550A1 Cyclic lactams as inhibitors of a-.beta. protein production
10/11/2001CA2402416A1 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity
10/10/2001EP1142905A1 Novel depsipeptide compound
10/10/2001EP1141375A1 Metallopeptide combinatorial libraries and applications
10/10/2001EP1141011A2 Compounds and methods to inhibit or augment an inflammatory response
10/10/2001EP1140985A1 Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators
10/10/2001EP1140984A1 Selective inhibitors of mmp-12
10/10/2001EP1140983A1 Bis-amino acid sulfonamides containing n-terminally a substituted benzyl group as hiv protease inhibitors
10/10/2001EP1140982A1 Synthesis and recovery of aspartame involving enzymatic deformylation step
10/10/2001EP1140981A1 Tripeptide compounds useful as selective inhibitors of aminopeptidase a and corresponding pharmaceutical compositions
10/10/2001EP1140980A1 Pseudopeptide compounds having an inhibiting activity with respect to paths activated by proteins with active tyrosine kinase activity and pharmaceutical compositions containing same
10/10/2001EP1140979A1 Polyol compounds, their production and use
10/10/2001EP1140918A1 Thrombin inhibitors
10/10/2001EP1140909A1 Novel inhibitors of farnesyl-protein transferase
10/10/2001EP1140864A2 Vitronectin receptor antagonist pharmaceuticals
10/10/2001EP1140837A1 Compounds useful in the treatment of inflammatory diseases
10/10/2001EP1140795A1 N-3, 3-dimethylbutyl-l-aspartic acid and esters thereof, the process of preparing the same, and the process for preparing n-[n-(3,3-dimethylbutyl)-l-alpha-aspartyl)-l-phenylalanine-1-methylester therefrom
10/10/2001EP1140204A2 Vitronectin receptor antagonist pharmaceuticals
10/10/2001EP1140203A2 Vitronectin receptor antagonist pharmaceuticals
10/10/2001EP1140202A1 Peptidic product, process and composition
10/10/2001EP1140194A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
10/10/2001EP1140193A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
10/10/2001EP1140192A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
10/10/2001EP1140183A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
10/10/2001EP1140182A2 Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia
10/10/2001EP1140179A2 Use of a cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
10/10/2001EP1140178A2 Use of a matrix metallaproteinase inhibitor and radiation as a combined treatment of neoplasia
10/10/2001EP1140177A2 Use of an integrin antagonist and radiation in the treatment of neoplasia
10/10/2001EP1139794A1 CO-CRYSTALLIZATION OF SUGAR AND N- N-(3,3-DIMETHYLBUTYL)-1-$g(a)-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER
10/10/2001EP0832065B1 Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
10/10/2001EP0830372B1 Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
10/10/2001CN1317012A Crystallization process for formation of stable crystal of aspartame derivative
10/10/2001CN1317011A Process for couping amino acids using bis-(trichloromethyl) carbonate
10/09/2001US6300514 Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
10/09/2001US6300501 Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
10/09/2001US6300337 Acetamide derivative and use thereof
10/09/2001CA2222296C Peptide and method of obtaining it
1 ... 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 ... 307